​

Dermata Therapeutics Stock (NASDAQ:DRMA)

ForecastOwnershipFinancialsChart
Dermata Therapeutics by TradingView

Previous Close

$1.04

52W Range

$1.01 - $13.35

50D Avg

$1.28

200D Avg

$2.89

Market Cap

$2.06M

Avg Vol (3M)

$281.80K

Beta

0.79

Div Yield

-

DRMA Company Profile

Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of hyperhidrosis and aesthetic conditions. The company was incorporated in 2014 and is headquartered in San Diego, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

8

IPO Date

Aug 13, 2021

Website

DRMA Performance

DRMA Financial Summary

Dec 23Dec 22Dec 21
Revenue---
Operating Income$-8.04M$-9.67M$-7.86M
Net Income$-7.79M$-9.61M$-7.95M
EBITDA$-8.04M$-9.67M$-7.86M
Basic EPS$-2.67$-13.92$-29.56
Diluted EPS$-2.67$-13.92$-29.56

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison

TickerCompany
ZVSAZyVersa Therapeutics, Inc.
PHIOPhio Pharmaceuticals Corp.
REVBRevelation Biosciences, Inc.
ENSCEnsysce Biosciences, Inc.
IMMXImmix Biopharma, Inc.
CYTOAltamira Therapeutics Ltd.
WINTWindtree Therapeutics, Inc.
ZURAZura Bio Limited
SONNSonnet BioTherapeutics Holdings, Inc.
HEPAHepion Pharmaceuticals, Inc.
CDIOCardio Diagnostics Holdings, Inc.
ATNF180 Life Sciences Corp.